[1]劉 陽,李新萍,吳細建.依達拉奉聯合腦苷肌肽治療重癥顱腦損傷患者的療效[J].醫學信息,2019,(22):103-104,111.[doi:10.3969/j.issn.1006-1959.2019.22.032]
 LIU Yang,LI Xin-ping,WU Xi-jian.Edaravone Combined with Cerebroside Carnosine in the Treatment of Patients with Severe Head Injury[J].Medical Information,2019,(22):103-104,111.[doi:10.3969/j.issn.1006-1959.2019.22.032]
點擊復制

依達拉奉聯合腦苷肌肽治療重癥顱腦損傷患者的療效()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
103-104,111
欄目:
臨床研究
出版日期:
2019-11-15

文章信息/Info

Title:
Edaravone Combined with Cerebroside Carnosine in the Treatment of Patients with Severe Head Injury
文章編號:
1006-1959(2019)22-0103-03
作者:
劉 陽李新萍吳細建
(余江縣人民醫院外一科,江西 余江 335200)
Author(s):
LIU YangLI Xin-pingWU Xi-jian
(Department of Surgery,Subject One,Yujiang County People's Hospital,Yujiang 335200,Jiangxi,China)
關鍵詞:
重癥顱腦損傷依達拉奉腦苷肌肽氧化應激神經營養因子
Keywords:
Severe craniocerebral injuryEdaravoneCerebroside carnosineOxidative stress Neurotrophic factor
分類號:
R651.1
DOI:
10.3969/j.issn.1006-1959.2019.22.032
文獻標志碼:
A
摘要:
目的 探討依達拉奉聯合腦苷肌肽治療重癥顱腦損傷患者的臨床效果。方法 選擇余江縣人民醫院2017年5月~2018年6月收診的重癥顱腦損傷患者50例,按照隨機數字表法分為觀察組與對照組,每組25例。對照組給予腦苷肌肽治療,觀察組則在對照組的基礎上聯合依達拉奉治療。比較兩組治療前后丙二醛(MDA)、超氧化物歧化酶(SOD)、髓過氧化物酶(MPO)、谷胱甘肽過氧化物酶(GSH-Px)、腦鈉肽(BNP)、神經元特異性烯醇化酶(NSE)、膠質原纖維酸性蛋白(GFAP)水平及臨床療效。結果 治療后兩組的MDA、MPO、NSE、GFAP水平均比治療前降低,SOD、GSH-Px、BNP水平均比治療前升高,且觀察組各指標改善程度優于對照組,差異均有統計學意義(P<0.05);觀察組的治療總有效率(96.00%)高于對照組(76.00%),差異有統計學意義(P<0.05)。結論 依達拉奉聯合腦苷肌肽治療重癥顱腦損傷的效果確切,可有效抑制患者機體的氧化應激水平,促進神經功能盡早恢復。
Abstract:
Objective To investigate the clinical effects of edaravone combined with cerebroside carnosine in the treatment of patients with severe craniocerebral injury. Methods A total of 50 patients with severe craniocerebral injury who were admitted to Yujiang County People's Hospital from May 2017 to June 2018 were enrolled. The patients were divided into observation group and control group according to the random number table method, 25 cases in each group. The control group was treated with cerebroside carnosine, and the observation group was treated with edaravone on the basis of the control group. Comparison of malondialdehyde (MDA), superoxide dismutase (SOD), myeloperoxidase (MPO), glutathione peroxidase (GSH-Px), brain natriuretic peptide (BNP) before and after treatment , neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP) levels and clinical efficacy. Results The levels of MDA, MPO, NSE and GFAP in the two groups were lower than those before treatment. The levels of SOD, GSH-Px and BNP were higher than those before treatment, and the improvement of each index in the observation group was better than that of the control group,the difference was statistically significant (P<0.05). The total effective rate of treatment in the observation group (96.00%) was higher than that in the control group (76.00%),the difference was statistically significant (P<0.05). Conclusion Edaravone combined with cerebroside carnosine is effective in the treatment of severe craniocerebral injury, which can effectively inhibit the oxidative stress level of patients and promote the early recovery of neurological function.

參考文獻/References:

[1]馬奔,張巖平,王銳,等.依達拉奉聯合腦苷肌肽治療重癥顱腦損傷的療效及對患者氧化應激和神經功能的影響[J].中國醫院用藥評價與分析,2019,19(3):317-319. [2]宋柳全,梁斗,黃中堅,等.腦苷肌肽注射液治療顱腦損傷療效觀察[J].創傷與急危重病醫學,2018,6(6):398-399. [3]鄒世斌,張誠.依達拉奉聯合腦苷肌肽輔助治療對重癥顱腦損傷患者神經功能損傷程度的影響[J].海南醫學院學報,2018, 24(5):640-642,646. [4]尹董文.探討依達拉奉聯合腦苷肌肽治療重癥顱腦損傷的臨床療效及安全性[J].系統醫學,2017,2(13):62-64. [5]Xie XY,Xu LI,Song JQ.Effect of edaravone combined with nimodipine on oxidative stress,inflammatory factors in patients with craniocerebral injury[J].Journal of Hainan Medical University,2016,22(21):24-27. [6]林其炎,張著,劉遠來.早期高壓氧聯合腦苷肌肽治療重型顱腦損傷的療效探討[J].黑龍江醫藥,2016,29(3):450-452. [7]Duan J.Observation of effects of mild hypothermia combined with Edaravone in treatment of acute severe craniocerebral injury[J].Medical Journal of Chinese Peoples Health,2016,29(5):38-40. [8]陳奇翰,林丹,鄧鋼,等.依達拉奉聯合腦苷肌肽治療重癥顱腦損傷的臨床研究[J].中國臨床藥理學雜志,2016,32(14):1261-1264.

更新日期/Last Update: 2019-11-15
中国足彩网竞彩